D. E. Shaw & Co., Inc. Cabaletta Bio, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 16,604 shares of CABA stock, worth $44,996. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,604
Previous 33,963
51.11%
Holding current value
$44,996
Previous $160,000
77.5%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CABA
# of Institutions
119Shares Held
44.8MCall Options Held
232KPut Options Held
68.5K-
Black Rock Inc. New York, NY4.76MShares$12.9 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.07MShares$11 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$9.85 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$7.77 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.76MShares$7.48 Million1.64% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $78.6M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...